• Skip to main content
  • Skip to primary sidebar
Transfusion News
  • About Us
  • Topics
    • Adverse Events (non-infectious)
    • Blood Donation
    • Cell Therapy
    • Coagulation & Plasma Transfusion
    • Platelet Transfusion
    • Policy and Guidelines
    • Quality Control and Regulatory
    • RBC Transfusion
    • Serology/Genotyping
    • Special Transfusion Situations
    • Transfusion Transmitted Infections
  • Continuing Education
  • Archives
  • Podcasts
  • Question of the Day
  • Search
  • Subscribe to Email Alerts
  • Follow us on
  • Search
  • Subscribe to Email Alerts

Jehovah’s Witness Governing Body Allows Autologous Transfusions

April 23, 2026

Jehovah’s Witnesses (JWs) are a Christian denomination founded in the late 19th century in the United States with a focus on evangelism and nontrinitarian beliefs. Since 1945, the Governing Body of the Jehovah’s Witnesses have prohibited the use of transfusions based on passages from the Old and New Testament of the Bible requiring believers to “abstain…from blood,” which they interpret as applying to both food and medicine even though the Bible does not comment on transfusions or medical procedures such as surgeries. While JWs have been allowed to individually determine how their own blood will be handled since 2000—such as whether to undergo simple blood tests, cell salvage during surgery, dialysis, etc.—they have been prohibited from all transfusions until now. The Governing Body Update #2 from March 2026 now allows JWs to remove and store their own blood for autologous transfusions during surgeries. While this is a significant change, critics argue that the update does not go far enough and allow allogeneic transfusions.

Reference:

MARCH 20, 2026 GLOBAL NEWS: 2026 Governing Body Update #2. Discussion of new policy starts at time 11:00. Jehovah’s Witnesses. 

Filed Under

  • News
  • RBC Transfusion
  • Uncategorized

Recommended

  • Transfusion Outcomes in Very-Low-Birth Weight Infants Associated with Donor Sex and Age

  • Sutimlimab, a Monoclonal Antibody, to Treat Cold Agglutinin Disease

  • Iron Supplementation May Reduce Deferral and Iron Deficiency in Blood Donors

Show Comments

Comments on this article are closed.

Get the latest news. Subscribe to our mailing list. Sign Up

Primary Sidebar

Latest News

  • Pre-Hospital Resuscitation with Low-Titer Type O Whole Blood for Trauma Patients

  • Double-knotting Blood Storage Bag Tubing Reduces Contamination

  • Costs of Type & Screen and Crossmatch Laboratory Tests for RBCs Higher in U.S. Compared to U.K.

  • Gene Editing of HBG1 and HBG2 Promotors to Treat β-Thalassemia and Sickle Cell Disease

    Question of the Day

    Copyright © 2026 John Wiley & Sons, Inc. All Rights Reserved.
    Privacy Policy

    Association for the Advancement of Blood and Biotherapies Wiley